Aranzazu Arias-Martinez, Eva Martínez de Castro, Javier Gallego, Virginia Arrazubi, Ana Custodio, Ana Fernández Montes, Marc Diez, Raquel Hernandez, María Luisa Limón, Juana María Cano, Rosario Vidal-Tocino, Ismael Macias, Laura Visa, Marta Martin Richard, Tamara Sauri, Cinta Hierro, Mireia Gil, Paula Cerda, Elia Martínez Moreno, Nieves Martínez Lago, Antonio José Mérida-García, Lucía Gómez González, Francisco Javier García Navalón, Maribel Ruiz Martín, Gema Marín, Flora López-López, Ana Belen Ruperez Blanco, Alejandro Francisco Fernández, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Felipe Alvarez-Manceñido
BACKGROUND: The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences in platinum-based regimens' safety and synergy with combination treatments need consideration. METHODS: We analyzed cases from the AGAMENON-SEOM Spanish registry of HER2-negative advanced esophagogastric adenocarcinoma treated with platinum and fluoropyrimidine from 2008 to 2021...
February 15, 2024: Clinical & Translational Oncology